Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
ENTRESTO SPRINKLE (SACUBITRIL; VALSARTAN) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
ENTRESTO SPRINKLE
NDA
Get alerts
SACUBITRIL; VALSARTAN | N218591 | NOVARTIS PHARMACEUTICALS CORP
2 strengths
3 unique patents
0 unique exclusivities
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Approvals
Label
Products
Patent Timeline
3 unique patents by expiration date
All strengths
6MG;6MG
15MG;16MG
Expiring < 1yr (2)
Active (1)
Today
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
Today
8877938
May. 27, 2027
9388134
Nov. 8, 2026
10722471
Feb. 2, 2037
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (2)
Sort:
Name
↑
Applicant
Strength
Approval
#001 — 6MG;6MG
RLD
3 patents
0 exclusivities
▴
CAPSULE, PELLETS;ORAL | Approved: Apr 12, 2024
Patents (3)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
8877938
May 27, 2027
—
Yes
Yes
—
—
9388134
Nov 8, 2026
—
—
—
U-1723
TREATMENT OF HEART FAILURE
—
10722471
Feb 2, 2037
—
—
Yes
U-3896
TREATMENT OF HEART FAILURE WITH ORAL PELLETS
—
#002 — 15MG;16MG
RLD
3 patents
0 exclusivities
▾
CAPSULE, PELLETS;ORAL | Approved: Apr 12, 2024